Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder

Overview

Symptomatic urinary tract infections (UTIs) are one of the main causes of morbidity and the main cause of re-hospitalization in subjects with neurogenic bladder. Long-term antibiotic therapy increases the risk of multi-resistant bacterial infections, without reducing the rate of symptomatic UTIs. Our non-comparative preliminary study has shown that Weekly Oral Cyclic Antibiotic Programme (single, weekly dose of antibiotic X on even weeks, and antibiotic Y on odd weeks) seem to drastically reduce both the number of symptomatic UTIs and the number of hospitalizations in patients with neurogenic bladder, without affecting bacterial ecology. The objective of this study is to validate this preliminary work with a large-scale randomized, parallel-group, multicenter study.

Full Title of Study: “A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2016

Interventions

  • Drug: Weekly Oral Cyclic Antibiotic programme
    • The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.

Arms, Groups and Cohorts

  • Experimental: Weekly Oral Cyclic Antibiotic programme
  • No Intervention: Classic care

Clinical Trial Outcome Measures

Primary Measures

  • Number of symptomatic UTIs
    • Time Frame: During the 6-month follow-up
    • Symptomatic UTIs are defined by the presence of infection or reinfection by the same bacteria, in combination with the presence of definite clinical signs of infection (autonomous hyper-reflexivity, spasticity, leakage, contractures, pyuria, fever, shivers).

Secondary Measures

  • The number of feverish UTIs
    • Time Frame: During the 6-month follow-up
    • The number of feverish UTIs
  • The number of hospitalizations
    • Time Frame: During the 6-month follow-up.
    • The number of hospitalizations
  • The duration of UTI-related hospitalizations
    • Time Frame: During the 6-month follow-up
    • The duration of UTI-related hospitalizations
  • The tolerance level to the Weekly Oral Cyclic Antibiotic Programme, measured by any adverse effects to antibiotics
    • Time Frame: During the 6-month follow-up.
    • The tolerance level to the Weekly Oral Cyclic Antibiotic Programme, measured by any adverse effects to antibiotics
  • The global antibiotic consumption.
    • Time Frame: During the 6-month follow-up
    • The global antibiotic consumption.
  • The number of urine culture negative
    • Time Frame: During the 6-month follow-up
    • The number of urine culture negative
  • The emergence of multi-resistant bacteria in urine (cultures), digestive bacteria (anal swabs), oro-pharynx bacteria (nasal swabs), and semi-quantitative research of multi-resistant bacteria in the stool.
    • Time Frame: During the 6-month follow-up
    • The emergence of multi-resistant bacteria in urine (cultures), digestive bacteria (anal swabs), oro-pharynx bacteria (nasal swabs), and semi-quantitative research of multi-resistant bacteria in the stool.
  • the quality of life
    • Time Frame: During the 6-month follow-up
    • A scale to measure the quality of life.

Participating in This Clinical Trial

Inclusion Criteria

  • subject over 18 years of age – having a neurogenic bladder with automatic catheter and pharmacologic disconnection of the detrusor muscle – having at least 4 symptomatic UTIs per year with bacterial sensitivity to the chosen antibiotics – having given full consent to participate in the study – being the recipient of social security benefits Exclusion Criteria:

  • known allergy or hypersensitivity to useful antibiotics (to which the bacterium or bacteria are sensitive) or to one of their components – other contraindication in the administering of useful antibiotics – urinary volume flow >500 ml during automatic catheter – different urinary drainage method than automatic catheter – occurrence of stones in the urinary tract – infection due to endo urinary material (urinary prosthesis, ureteral stent) – creatinine clearance <60 ml/min – patient under guardianship – women who are pregnant, nursing, or who may become pregnant

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Tours
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Louis BERNARD, MD-PhD, Principal Investigator, University Hospital, Tours

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.